• LAST PRICE
    0.7100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.7100
  • Day Range
    ---
  • 52 Week Range
    Low 0.3800
    High 1.1497
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.7233
TimeVolumeFBRX
09:32 ET2850.7416
10:14 ET1000.742999
11:08 ET1000.725
12:39 ET5000.724999
01:51 ET15000.721
02:02 ET30000.7101
03:27 ET1100.71
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesFBRX
Forte Biosciences Inc
25.8M
-0.6x
---
United StatesCERO
CERo Therapeutics Holdings Inc
25.8M
-4.6x
---
United StatesITRM
Iterum Therapeutics PLC
25.8M
-0.5x
---
United StatesACXP
Acurx Pharmaceuticals Inc
25.8M
-1.4x
---
United StatesSNSE
Sensei Biotherapeutics Inc
25.2M
-0.8x
---
United StatesUBX
UNITY Biotechnology Inc
25.2M
-0.6x
---
As of 2024-04-16

Company Information

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.

Contact Information

Headquarters
3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
Phone
310-618-6994
Fax
302-655-5049

Executives

Chairman of the Board, Chief Executive Officer
Paul Wagner
President, Chief Scientific Officer
Hubert Chen
Chief Financial Officer
Antony Riley
Independent Director
Scott Brun
Independent Director
Stephen Doberstein

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$25.8M
Revenue (TTM)
$0.00
Shares Outstanding
36.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.47
EPS
$-1.19
Book Value
$0.97
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.